Trials / Withdrawn
WithdrawnNCT03738111
Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma
A Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Lee's Pharmaceutical Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-centre, open-label, dose escalation, Phase 1 study. The primary objective is to determine the highest dose of TG02 citrate that can safely be given to patients with advanced hepatocellular carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TG02 Citrate | TG02 citrate capsules |
Timeline
- Start date
- 2018-12-01
- Primary completion
- 2021-08-01
- Completion
- 2021-12-01
- First posted
- 2018-11-13
- Last updated
- 2019-09-25
Source: ClinicalTrials.gov record NCT03738111. Inclusion in this directory is not an endorsement.